The role of the neurovascular scalp structures in migraine

Cephalalgia

Volumn 32, Issue 10, 2012, Pages 778-784

  Cianchetti, Carlo ^a  

^a DEPARTMENT OF RADIOLOGY   (Italy)

Author keywords

arteries; Migraine; neurovascular; periarterial nociceptive fibres; scalp arteries

Indexed keywords

BOTULINUM TOXIN A; BUPIVACAINE; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; CARBACHOL; GLYCERYL TRINITRATE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; LIDOCAINE; MENTHOL; OLCEGEPANT; PROSTACYCLIN; PROSTAGLANDIN D2; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 2A RECEPTOR; SILDENAFIL; SODIUM CHLORIDE; SUMATRIPTAN;

ARTERY BLOOD FLOW; ARTERY COMPRESSION; CREAM; DRUG ADMINISTRATION ROUTE; DRUG INDICATION; HEADACHE; HUMAN; MIDDLE CEREBRAL ARTERY; MIGRAINE; NERVE BLOCK; NERVE FIBER; NEUROVASCULAR SCALP; NOCICEPTION; PERCUTANEOUS DRUG ADMINISTRATION; REVIEW; SCALP; SUPERFICIAL TEMPORAL ARTERY; TRANSFORMED MIGRAINE; TREATMENT OUTCOME; VASODILATATION;

HUMANS; MIGRAINE DISORDERS; NOCICEPTORS; PAIN; SCALP;

EID: 84864262756     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102412449930     Document Type: Review

References (77)

1. Olesen J, Burstein R, Ashina M, et al. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol. 2009 ; 8: 679-690
2. Shevel E. The extracranial vascular theory of migraine-a great story confirmed by the facts. Headache. 2011 ; 51: 409-417
3. Dodick DW. Examining the essence of migraine-is it the blood vessel or the brain? A debate. Headache. 2008 ; 48: 661-667
4. Blau JN, Dexter SL. The site of pain origin during migraine attacks. Cephalalgia. 1981 ; 1: 143-147
5. Drummond PD, Lance JW. Extracranial vascular changes and the source of pain in migraine headache. Ann Neurol. 1983 ; 13: 32-37
6. Lipton SA. Prevention of classic migraine headache by digital massage of the superficial temporal arteries during visual aura. Ann Neurol. 1986 ; 19: 515-516
7. Vijayan N. Head band for migraine headache relief. Headache. 1993 ; 33: 40-42
8. Hmaidan Y, Cianchetti C. Effectiveness of a prolonged compression of scalp arteries on migraine attacks. J Neurol. 2006 ; 253: 811-812
9. Cianchetti C, Cianchetti ME, Pisano T, et al. Treatment of migraine attack by compression of temporal superficial arteries using a device. Med Sci Monit. 2009 ; 15: 185-188
10. Cianchetti C, Serci MC, Pisano T, et al. Compression of superficial temporal arteries by a handmade device: a simple way to block or attenuate migraine attacks in children and adolescents. J Child Neurol. 2010 ; 25: 67-70
11. Iversen HK, Nielsen TH, Olesen J, et al. Arterial responses during migraine headache. Lancet. 1990 ; 336: 837-839
12. Cianchetti C, Ledda MG, Serci MC, et al. Painful scalp arteries in migraine. J Neurol. 2010 ; 257: 1642-1648
13. Cianchetti C, Serci MC, Madeddu F, et al. Pressure-painful scalp arteries in children and adolescents suffering from migraine. Cephalalgia. 2011 ; 31: 1576-1579
14. Tfelt-Hansen P, Lous I, Olesen J. Prevalence and significance of muscle tenderness during common migraine attacks. Headache. 1981 ; 21: 49-54
15. Jensen K, Tuxen C, Olesen J. Pericranial muscle tenderness and pressure-pain threshold in the temporal region during common migraine. Pain. 1988 ; 35: 65-70
16. Jensen R, Rasmussen BK, Pedersen B, et al. Muscle tenderness and pressure pain thresholds in headache. A population study. Pain. 1993 ; 52: 193-199
17. Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol. 2000 ; 47: 614-624
18. Hinsey JC. Observations on the innervation of blood vessels in skeletal muscles. J Comp Neurol. 1928 ; 47: 23-65
19. Cianchetti C, Hmaidan Y. Saline pomphus around scalp arteries can block migraine pain. J Neurol. 2007 ; 254: 1746-1747
20. Cianchetti C, Hmaidan Y, Finco G, et al. Scalp periarterial saline effect on migraine attacks: percentage of positive responses and relation to type of pain. J Neurol. 2009 ; 256: 1109-1113
21. Gawel MJ, Rothbart PJ. Occipital nerve block in the management of headache and cervical pain. Cephalalgia. 1992 ; 12: 9-13
22. Ashkenazi A, Young WB. The effects of greater occipital nerve block and trigger point injection on rush allodynia and pain in migraine. Headache. 2005 ; 45: 350-354
23. Ashkenazi A, Matro R, Shaw JW, et al. Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: A randomised comparative study. J Neurol Neurosurg Psychiatry. 2008 ; 79: 415-417
24. Weibelt S, Andress-Rothrock D, King W, et al. Suboccipital nerve blocks for suppression of chronic migraine: safety, efficacy, and predictors of outcome. Headache. 2010 ; 50: 1041-1044
25. Bovim G, Sand T. Cervicogenic headache, migraine without aura and tension-type headache: diagnostic blockade of greater occipital and supra-orbital nerves. Pain. 1992 ; 51: 43-48
26. Pearce JMS. Greater occipital nerve block: a diagnostic test?. Adv Clin Neurosci Rehab. 2008 ; 8: 15-17
27. Afridi SK, Shields KG, Bhola R, et al. Greater occipital nerve injection in primary headache syndromes-prolonged effects from a single injection. Pain. 2006 ; 122: 126-129
28. Deshpande KK, Wininger KL. Feasibility of combined epicranial temporal and occipital neurostimulation: treatment of a challenging case of headache. Pain Physician. 2011 ; 14: 37-44
29. Tfelt-Hansen P, Olesen J, Lous I. Lignocaine versus saline in migraine pain. Lancet. 1980 ; 1: 1140-1140
30. Giamberardino MA, Tafuri E, Savini A, et al. Contribution of myofascial trigger points to migraine symptoms. J Pain. 2007 ; 8: 869-878
31. Jensen K. Extracranial blood flow, pain and tenderness in migraine. Clinical and experimental studies. Acta Neurol Scand Suppl. 1993 ; 147: 1-27
32. Wolff HG Headache and Other Head Pain. 2 nd edn. Oxford: Oxford University Press, 1963. Oxford: Oxford University Press ; 1963 :
33. Iversen HK, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia. 1996 ; 16: 412-418
34. Petersen KA, Lassen LH, Birk S, et al. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther. 2005 ; 77: 202-213
35. Wienecke T, Olesen J, Ashina M. Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineurs. Cephalalgia. 2010 ; 30: 179-190
36. Wienecke T, Olesen J, Oturai PS, et al. Prostacyclin (epoprostenol) induces headache in healthy subjects. Pain. 2008 ; 139: 106-116
37. Schytz HW, Wienecke T, Oturai PS, et al. The cholinomimetic agent carbachol induces headache in healthy subjects. Cephalalgia. 2009 ; 29: 258-268
38. Schytz HW, Wienecke T, Olesen J, et al. Carbachol induces headache, but not migraine-like attacks, in patients with migraine without aura. Cephalalgia. 2010 ; 30: 337-345
39. Wienecke T, Olesen J, Ashina M. Discrepancy between strong cephalic arterial dilatation and mild headache caused by prostaglandin D2 (PGD2). Cephalalgia. 2011 ; 31: 65-76
40. Hansen JM, Sitarz J, Birk S, et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia. 2006 ; 26: 992-1003
41. Rahmann A, Wienecke T, Hansen JM, et al. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia. 2008 ; 28: 226-236
42. Petersen KA, Birk S, Kitamura K, et al. Effect of adrenomedullin on the cerebral circulation: relevance to primary headache disorders. Cephalalgia. 2009 ; 29: 23-30
43. Kruuse C, Thomsen LL, Birk S, et al. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain. 2003 ; 126: 241-247
44. Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005 ; 25: 139-147
45. Ashina M, Tfelt-Hansen P, Dalgaard P, et al. Lack of correlation between vasodilatation and pharmacologically induced immediate headache in healthy subjects. Cephalalgia. 2011 ; 31: 683-690
46. Schoonman GG, van der Grond J, Kortmann C, et al. Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3T magnetic resonance angiography study. Brain. 2008 ; 131: 2192-2200
47. Asghar MS, Hansen AE, Amin FM, et al. Evidence for a vascular factor in migraine. Ann Neurol. 2011 ; 69: 635-645
48. Asghar MS, Hansen AE, Kapijimpanga T, et al. Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology. 2010 ; 75: 1520-1526
49. Nagata E, Moriguchi H, Takizawa S, et al. The middle meningial artery during a migraine attack: 3T magnetic resonance angiography study. Intern Med. 2009 ; 48: 2133-2135
50. Schytz HW, Birk S, Wienecke T, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009 ; 132: 16-25
51. Amin FM, Asghar MS, Guo S, et al. Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia. 2012 ; 32: 140-149
52. Ahn AH. On the temporal relationship between throbbing migraine pain and arterial pulse. Headache. 2010 ; 50: 1507-1510
53. Jansen I, Olesen J, Edvinsson L. 5-Hydroxytryptamine receptor characterization of human cerebral, middle meningeal and temporal arteries: regional differences. Acta Physiol Scand. 1993 ; 147: 141-150
54. Verheggen R, Freudenthaler S, Meyer-Dulheuer F, et al. Participation of 5-HT1-like and 5-HT2A receptors in the contraction of human temporal artery by 5-hydroxytryptamine and related drugs. Br J Pharmacol. 1996 ; 117: 283-292
55. Verheggen R, Hundeshagen AG, Brown AM, et al. 5-HT1B receptor-mediated contractions in human temporal artery: evidence from selective antagonists and 5-HT receptor mRNA expression. Br J Pharmacol. 1998 ; 124: 1345-1354
56. van den Broek RW, Bhalla P, VanDenBrink AM, et al. Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization. Cephalalgia. 2002 ; 22: 83-93
57. Verheggen R, Meier A, Werner I, et al. Functional 5-HT receptors in human occipital artery. Naunyn Schmiedebergs Arch Pharmacol. 2004 ; 369: 391-401
58. Jansen I, Uddman R, Hocherman M, et al. Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P, and calcitonin gene-related peptide in human temporal arteries. Ann Neurol. 1986 ; 20: 496-501
59. Uddman R, Edvinsson L, Jansen I, et al. Peptide-containing nerve fibres in human extracranial tissue: a morphological basis for neuropeptide involvement in extracranial pain?. Pain. 1986 ; 21: 391-399
60. Jansen Olesen I, Gulbenkian S, Valenca A, et al. The peptidergic innervation of the human superficial temporal artery: immunohistochemistry, ultrastructure, and vasomotility. Peptides. 1995 ; 16: 275-287
61. Jansen I, Uddman R, Ekman R, et al. Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: comparison with cerebral and temporal arteries. Peptides. 1992 ; 13: 527-536
62. Verheggen R, Bumann K, Kaumann AJ. BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37). Br J Pharmacol. 2002 ; 136: 120-126
63. Sultaneh A. Migraine: new surgical treatment. In: Congress of Neurological Surgeons, San Diego, CA, 29 September-4 October 2001, Abstract no. 173.
64. Shevel E. Vascular surgery for chronic migraine. Therapy. 2007 ; 4: 451-456
65. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010 ; 30: 804-814
66. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010 ; 50: 921-936
67. Gazerani P, Au S, Dong X, et al. Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis. Pain. 2010 ; 151: 606-616
68. Cianchetti C. Capsaicin jelly against migraine pain. Int J Clin Pract. 2010 ; 64: 457-459
69. Del Fiacco M, Serra MP, Quartu M, et al. Transient receptor potential vanilloid type-1 (TRPV1) in the human trigeminal system and arteries of the scalp. Int Symp Morphol Sci. :
70. Evans MS, Cheng X, Jeffry JA, et al. Sumatriptan inhibits TRPV1 channels in trigeminal neurons. Headache. 2012 ; 52: 773-784
71. Summ O, Holland PR, Akerman S, et al. TRPV1 receptor blockade is ineffective in different in vivo models of migraine. Cephalalgia. 2011 ; 31: 172-180
72. Dalsgaard-Nielsen T. Migraine diagnostics with special reference to pharmacological tests. Int Arch Allergy. 1955 ; 7: 312-322
73. Hansen HJ, Drewes VM. The nitroglycerine ointment test-a double-blind examination. Dan Med Bull. 1970 ; 17: 226-229
74. Borhani Haghighi A, Motazedian S, Rezaii R, et al. Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: a randomised, double-blind, placebo-controlled, crossed-over study. Int J Clin Pract. 2010 ; 64: 451-456
75. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol. 1984 ; 16: 157-168
76. Kosaras B, Jakubowski M, Kainz V, et al. Sensory innervation of the calvarial bones of the mouse. J Comp Neurol. 2009 ; 515: 331-348
77. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011 ; 12: 570-584